$2.51
-0.13-4.92%
At close: -
$2.50
-0.0100-0.40%
After Hours: 4:55 PM EDT
Comments
Loading...
Moleculin Biotech (NASDAQ:MBRX) Stock, Analyst Ratings, Price Targets, Forecasts
Moleculin Biotech Inc has a consensus price target of $14 based on the ratings of 4 analysts. The high is $40 issued by Roth MKM on April 12, 2024. The low is $3 issued by HC Wainwright & Co. on December 14, 2023. The 3 most-recent analyst ratings were released by Maxim Group, Roth MKM, and Maxim Group on November 12, 2024, April 12, 2024, and March 26, 2024, respectively. With an average price target of $22.67 between Maxim Group, Roth MKM, and Maxim Group, there's an implied 806.67% upside for Moleculin Biotech Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
Roth MKM
HC Wainwright & Co.
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Moleculin Biotech
Data brought to you by Benzinga APIs
FAQ
What is the target price for Moleculin Biotech (MBRX) stock?
The latest price target for Moleculin Biotech (NASDAQ:MBRX) was reported by Maxim Group on November 12, 2024. The analyst firm set a price target for $8.00 expecting MBRX to rise to within 12 months (a possible 220.00% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Moleculin Biotech (MBRX)?
The latest analyst rating for Moleculin Biotech (NASDAQ:MBRX) was provided by Maxim Group, and Moleculin Biotech maintained their buy rating.
When was the last upgrade for Moleculin Biotech (MBRX)?
There is no last upgrade for Moleculin Biotech
When was the last downgrade for Moleculin Biotech (MBRX)?
There is no last downgrade for Moleculin Biotech.
When is the next analyst rating going to be posted or updated for Moleculin Biotech (MBRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Moleculin Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Moleculin Biotech was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.
Is the Analyst Rating Moleculin Biotech (MBRX) correct?
While ratings are subjective and will change, the latest Moleculin Biotech (MBRX) rating was a maintained with a price target of $20.00 to $8.00. The current price Moleculin Biotech (MBRX) is trading at is $2.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.